EXPERIMENTAL DRUG DEVELOPEMENT CENTRE

Company Introduction: EXPERIMENTAL DRUG DEVELOPMENT CENTRE (EDDC)

Company Nature: Research and Development Institution

The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development. It operates under the Agency for Science, Technology and Research (A*STAR), Singapore's leading public sector agency dedicated to scientific discovery and technological innovation. EDDC's primary mission is to translate early-stage scientific discoveries into novel drug candidates, addressing unmet medical needs.

EDDC serves as a crucial bridge between fundamental scientific research and clinical development within the pharmaceutical pipeline. It brings together a multidisciplinary team of experts, including scientists, chemists, biologists, and pharmacologists, who focus on various therapeutic areas such as oncology, infectious diseases, and neurological disorders. Their work encompasses target validation, hit identification, lead optimization, and preclinical development, all aimed at generating high-quality drug candidates suitable for advancement into clinical trials or for licensing to pharmaceutical partners for further development and commercialization.

EDDC is fundamentally a research and development organization. It is neither a factory involved in the manufacturing of drugs nor a trading company that deals with the buying and selling of existing pharmaceutical products. Its core function is to create the foundational scientific and preclinical data necessary to develop new medicines.

The Experimental Drug Development Centre (EDDC) in Singapore is a national platform for drug discovery and development. It does not typically manufacture or sell commercial drug products directly to the public. Instead, its primary outputs and focus areas include:

1. Drug Candidates: Developing novel therapeutic compounds through various stages of preclinical research.

2. Intellectual Property: Generating patents and proprietary technologies related to drug discovery and development.

3. Research Collaborations: Partnering with pharmaceutical companies, biotechnology firms, and academic institutions to advance drug candidates.

4. Preclinical Development: Conducting studies to assess the safety and efficacy of potential drugs before human trials.

5. Disease Focus Areas: Researching treatments for various diseases, often including oncology, infectious diseases, and neurological disorders.

6. Technology Platforms: Developing and utilizing advanced platforms for drug screening, target validation, and medicinal chemistry.